Global Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market 2025–2029: Unveiling Growth Developments with the Latest Updates
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Today And What Is Its Future Size?
There has been a steady increase in the market size of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) in the past few years. The market is set to grow from $5.57 billion in 2024 to $5.97 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. Factors contributing to the growth during the historical period include a surge in PNH and aHUS cases, increased funding for research on rare diseases, and a growing demand for targeted therapies. Additionally, heightened awareness about PNH and aHUS, coupled with an increase in the use of complement inhibitors, has also played a part in the market growth.
The market size for paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) is projected to experience robust growth in the forthcoming years, escalating to $7.88 billion in 2029 with a 7.2% compound annual growth rate (CAGR). This expected growth over the period can be ascribed to factors such as increased approvals for novel treatments by regulatory bodies, growing partnerships between biotech corporations and research institutions, the upsurge in demand for personalized medication, rising funds in startups focusing on rare diseases and an increase in clinical trials and research studies. Noteworthy trends during the forecast period encompass advancements in complement inhibition treatments, inclusion of gene therapy methods, progress in personalized medicine, technological advancements in diagnostic tools, and remote patient monitoring through integrated technology.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24357&type=smp
Which Demand Drivers Are Strengthening The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
The increase in occurrences of rare diseases is anticipated to fuel the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market. These infrequent diseases impact a small proportion of the population, typically less than 200,000 individuals and are typically marked by their intricacy, severity, and the need for specialized care. The rise in rare diseases can be linked to advancements in diagnostic tools, which offer superior detection and recognition of conditions that were previously underreported or undiagnosed. PNH and aHUS aid in comprehending and managing rare diseases by offering insights into the pathophysiology and potential therapeutic targets for conditions that have limited treatment options. For instance, in November 2024, the Food and Drug Administration, a US federal agency, revealed that over 7,000 rare diseases affected more than 30 million individuals in the United States. Hence, the increasing frequency of rare diseases underscores the growth of the PNH and aHUS market.
Which Segment Accounts For The Largest Share In The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)market covered in this report is segmented –
1) By Type: Soliris; Ultomiris
2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria(PNH); Atypical Hemolytic Uremic Syndrome(aHUS)
3) By Treatment Type: Complement Inhibitors; Plasma Exchange Or Infusion; Other Symptomatic Treatments
4) By Diagnosis Method: Clinical Diagnosis; Genetic Testing; Biomarker Testing
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other Users
Subsegments:
1) By Soliris: Eculizumab For PNH; Eculizumab For aHUS; Eculizumab Biosimilars
2) By Ultomiris: Ravulizumab For PNH; Ravulizumab For aHUS; Ravulizumab Extended-Interval Dosing
Which Disruptive Trends Are Driving Change Across The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market?
Firms that are major players in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) markets are prioritising the development of ground-breaking products like complement inhibitors, with a goal of enhancing patient outcomes and ease of treatment. Complement inhibitors are therapeutic substances designed to obstruct specific elements of the complement system, an immune system part that aids in pathogen and damaged cell disposal. For instance, Novartis AG, a Swiss pharmaceutical company, in December 2023, received clearance from the United States Food and Drug Administration (FDA) for Fabhalta (iptacopan), marking it as the first oral monotherapy for treating adults with paroxysmal nocturnal hemoglobinuria, and boasts improved hemoglobin levels without the necessity for transfusions. This novel complement inhibitor functions by curbing Factor B in the alternate complement pathway, thus providing an all-encompassing control over both intravascular and extravascular hemolysis. Its oral application simplifies the disease handling process and enhances patient life quality, thereby eradicating the issues related to regular infusions.
Which Companies Hold A Competitive Edge In The 1733 Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market are Roche Holding AG, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Alexion Pharmaceuticals Inc., UCB Pharma Limited, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Genentech Inc., Omeros Corporation, CinnaGen Co., Apellis Pharmaceuticals Inc., CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, NovelMed Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Akari Therapeutics plc
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market In The Coming Years?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24357&type=smp
Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market 2025, By The Business Research Company
Acute Coronary Syndrome Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report
Acute Respiratory Distress Syndrome Ards Global Market Report 2025
Antiphospholipid Syndrome Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
